Toggle Sidebar
Tracking
The Digest
Dashboard
Changes
Readouts
Trials
Companies
Comparisons
Automation
Nightly sweep
Settings
Tracker
↳
Sign in
Sign in
Explore the registry
Track Ritlecitinib 50 mg's trials
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Ritlecitinib 50 mg
Ongoing
Recruiting
Phase 2
Open NCT07219615 on ClinicalTrials.gov ↗
Population
Loading…
Intervention
Loading…
Comparator
Loading…
Outcomes
Loading…
Overview
Endpoints
Eligibility
Full record
